For the longest time scientists have searched for a drug to help cure cancer. Now they have tried out another one; Fenbendazole.
Can it be the drug to help cure cancer?
According to a case series published in an oncology journal, the answer could be a resounding yes. The case report highlights three cancer patients who were in pretty bad shape. But after taking Fenbendazole, they all experienced a complete remission. What Is Fenbendazole, and How Does it Work? Fenbendazole (FBZ) is a medicine originally designed to treat worms and parasites in animals. Its sister drugs, Mebendazole and Albendazole, have had remarkable success treating similar ailments in humans with few side effects. Recently, anecdotal reports have praised Fenbendazole as a potentially miraculous anti-cancer drug. It works by destabilizing microtubules, the structures that help cancer cells divide and grow. By disrupting this process, Fenbendazole effectively halts cancer cell division and slows or stops tumor growth. Miraculous Recoveries After Taking Fenbendazole Case series #1 features a 63-year-old man with advanced kidney cancer (clear cell renal carcinoma) who experienced tumor recurrence and severe side effects from multiple cancer therapies, including surgery and two different medications. With no effective options left, he turned to Fenbendazole (FBZ), taking 1 gram three times a week at a friend’s suggestion. Over the next 10 months, his tumors—including those in his pancreas and spine—showed near-complete resolution on imaging. Remarkably, he experienced no side effects from FBZ, and follow-up scans have shown no signs of recurrence. Case series #2 follows a 72-year-old man with metastatic urethral cancer that had spread to his lungs, lymph nodes, and brain. Despite undergoing multiple rounds of chemotherapy and radiation, one lymph node continued to grow, resisting all treatments. Seeking alternatives, he decided to try Fenbendazole (FBZ), taking 1 gram three times a week, along with vitamin E, curcumin, and CBD oil, while postponing further conventional therapies. Over the next nine months, imaging revealed a dramatic response, with the lymph node shrinking significantly until it completely resolved. Remarkably, he reported no side effects during this period. Case series #3 focuses on a 63-year-old woman diagnosed with a large, invasive bladder tumor. Facing a challenging prognosis, she underwent chemotherapy while also taking fenbendazole (FBZ) at 1 gram three times a week. After completing six cycles of treatment, follow-up scans showed a complete resolution of the tumor, with only minimal thickening remaining in the bladder wall. Confident in her recovery, she chose to decline further surgery and remains disease-free under regular surveillance. The abstract concluded, “FBZ appears to be a potentially safe and effective antineoplastic agent that can be repurposed for human use in treating genitourinary malignancies.” Reflecting on these remarkable case reports, Dr. John Campbell urged drug regulators to “start looking at this as a matter of some urgency because people are dying from cancer now.” “So if something is safe and effective, surely it can be accredited for human use by our national authorizing agencies pretty quickly if they want to,” Dr. Campbell added with a hint of sarcasm. Of course, the key words here are “if they want to.” “Three patients, basically… cured of their cancers. Read the paper for yourself. That’s what they seem to be saying to me.”
From @VigilantFox on “X”.
The paper can be found here:
Russia presented the news they have made a vaccine for cancer not that long ago as well.
https://www.rt.com/russia/599039-russia-cancer-vaccine-progress/
And users of this forum will probably be aware of the work. that has been done suggesting that cancer can be cured with two sources of frequencies, that together kills the cancer cells.
Locking in the key words “Latest in cancer treatment” in the search box, this is what comes up, showing there’s a long range of different methods being tried at the moment.
- CAR T-cell therapy: Chimeric Antigen Receptor (CAR) T-cell therapy has shown promising results in treating aggressive lymphomas, including relapsed-refractory diffuse large B-cell lymphoma (DLBCL). Studies have demonstrated long-term remission and even cure rates in some patients.
- Nanomedicine approach: Researchers at the University of Chicago have developed a nanomedicine that increases the penetration and accumulation of chemotherapy drugs in tumor tissues, effectively killing cancer cells in mice.
- Combination therapy: The ComboMATCH initiative by the National Cancer Institute (NCI) aims to test new drug combinations guided by tumor biology, potentially leading to more effective treatments.
- Immunotherapy: Liquid biopsies may improve survival in people with lung cancer, according to an international study led by MSK investigators. Liquid biopsies detect small amounts of cancer DNA in the blood, allowing for targeted therapies.
- Targeted therapies: FDA approved afami-cel (Tecelra) to treat metastatic synovial sarcoma, a type of soft tissue sarcoma. Researchers have also identified hundreds of promising targets for existing drugs or potential new cancer drugs using proteogenomic data from over 1,000 tumors.
- Theranostics: The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for metastatic castration-resistant prostate cancer positive for prostate-specific membrane antigen (PSMA). This targeted radiodrug uses radioactive substances to visualize and destroy cancer cells.
- Focal therapy: MSK researchers have developed an advanced focal therapy approach called high-intensity focused ultrasound (HIFU) for prostate cancer, guided by magnetic resonance imaging (MRI).
- Cobimetinib: MSK investigators found that cobimetinib, a targeted drug approved for melanoma, may be effective in treating histiocytosis.
- Second cancers after CAR T-cell therapy: The FDA is investigating instances of second cancers following treatment with CAR T-cell therapies. NCI’s Dr. Stephanie Goff explains that second cancers are rare and emphasizes the importance of continued research.
- Precision cancer therapies: Researchers are exploring strategies to disrupt non-homologous end-joining (NHEJ), a mechanism by which cancer cells develop resistance to targeted therapies.
These developments highlight the ongoing efforts to improve cancer treatment outcomes, including the use of immunotherapy, targeted therapies, and combination approaches.
I guess since AI is soon to take over the globe in most areas, why not throw some cures at them as they’re heading out anyway?
